Yağ asidi kompozisyonu ile hipertansiyon arasındaki ilişki ve farmakoterapötik yaklaşımların etkileri: kesitsel bir çalışma

Abstract

Amaç: Yağ asitleri (YA) ile hipertansiyon (HT) arasındaki ilişki, HT patogenezinde yer aldıklarına dair kanıtlara rağmen tam olarak anlaşılmamıştır. Kardiyovasküler ilaçların YA kompozisyonunu değiştirdiğinin gösterilmiş olması, bu ilaçların ikincil kardiyovasküler etkilerini düşündürmektedir. Bu çalışmanın amacı, YA kompozisyonu ile HT arasındaki ilişkiyi ve kardiyovasküler ilaçların YA kompozisyonu üzerindeki etkilerini araştırmaktır. Gereç ve yöntem: Çalışmaya HT (n=69) ve kontrol (n=66) grupları dahil edilmiştir. Eritrosit hücre zarlarının YA kompozisyonu analiz edilmiş ve kardiyovasküler ilaçların YA kompozisyonu üzerindeki etkileri binomial lojistik regresyon ile değerlendirilmiştir. Bulgular: Hipertansif hastalarda, kontrol grubuna kıyasla, daha yüksek pentadekanoik asit, palmitik asit, palmitoleik asit, oleik asit, toplam doymuş yağ asitleri (SFA) ve toplam tekli doymamış yağ asitleri (MUFA) düzeyleri ve daha düşük linoleik asit (LA), dokosahekzaenoik asit (DHA), toplam çoklu doymamış yağ asitleri (PUFA) ve Omega 3 İndeksi düzeyleri gözlemlenmiştir. Delta-6-desaturaz (D6D) ve stearoyl-CoA-desaturaz (SCD) aktiviteleri HT grubunda daha yüksek bulunmuştur. Diüretikler, oleik asidi (OR:0,129; %95CI:0,021-0,803; p=0,028), toplam MUFA'ları (OR:0,098; %95CI:0,015-0,636; p=0,015) ve SCD indeksini (OR:0,129; %95CI:0,021-0,803; p=0,028) azaltırken, statinler gama-linolenik asidi (GLA) (OR:18,596; %95CI:1,041-332,087; p=0,047) artırmıştır. Renin-anjiyotensin sistemi ilaçları toplam PUFA'ları azaltmıştır (OR:0,188; %95CI:0,053-0,663; p=0,009). Sonuç: Bulgular, YA kompozisyonundaki değişiklikler ile HT arasındaki ilişkiyi göstermekte ve kardiyovasküler ilaçların YA kompozisyonunu etkileyebileceğini düşündürmektedir.

Keywords

• Hipertansiyon
• yağ asidi kompozisyonu
• omega-3 indeksi
• kardiyovasküler ilaçlar

The association between fatty acid composition and hypertension and the effects of pharmacotherapeutic approaches: a cross-sectional study

Abstract

Purpose: The relationship between fatty acids (FAs) and hypertension (HT) is not fully understood, despite evidence of their involvement in HT pathogenesis. Cardiovascular drugs have been shown to alter FA composition, suggesting secondary cardiovascular effects. This study aimed to investigate the association between FA composition and HT, as well as the impact of cardiovascular drugs on FA composition. Materials and methods: The study included HT (n=69) and control (n=66) groups. The FA compositions of erythrocyte cell membranes were analyzed, and the effects of cardiovascular drugs on FA composition were evaluated using binomial logistic regression. Results: Hypertensive patients exhibited higher levels of pentadecanoic acid, palmitic acid, palmitoleic acid, oleic acid, total saturated fatty acids (SFAs), and total monounsaturated fatty acids (MUFAs), and lower levels of linoleic acid (LA), docosahexaenoic acid (DHA), total polyunsaturated fatty acids (PUFA), and Omega 3 Index compared to controls. Delta-6-desaturase (D6D) and stearoyl-CoA-desaturase (SCD) activities were higher in the HT group. Diuretics reduced oleic acid (OR:0.129; 95%CI:0.021-0.803; p=0.028), total MUFAs (OR:0.098; 95%CI:0.015-0.636; p=0.015), and SCD index (OR:0.129; 95%CI:0.021-0.803; p=0.028), while statins enhanced gamma-linolenic acid (GLA) (OR:18.596; 95%CI:1.041-332.087; p=0.047). Renin-angiotensin system drugs decreased total PUFAs (OR:0.188; 95%CI:0.053-0.663; p=0.009). Conclusions: The findings demonstrate an association between FA composition changes and HT and suggest that cardiovascular drugs can influence FA composition.

Keywords

• Hypertension
• fatty acid composition
• omega-3 index
• cardiovascular drugs

References

1. Ayhan İ, Çam SA, Uysal F, Arslan SO. The importance of fatty acid composition changes in terms of cardiovascular diseases. Turkish J Clinics and Laboratory. 2020;4:323-333. doi:10.18663/tjcl.687043
2. De Craene JO, Bertazzi DL, Bär S, Friant S. Phosphoinositides, Major Actors in Membrane Trafficking and Lipid Signaling Pathways. Int J Mol Sci. 2017;18(3):634. doi:10.3390/ijms18030634
3. Sarri KO, Linardakis MK, Bervanaki FN, Tzanakis NE, Kafatos AG. Greek Orthodox fasting rituals: a hidden characteristic of the Mediterranean diet of Crete. Br J Nutr. 2004;92(2):277-284. doi:10.1079/BJN20041197
4. Sarafidis PA, Bakris GL. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance? J Hum Hypertens. 2007;21(1):12-19. doi:10.1038/sj.jhh.1002103
5. Liu YX, Yu JH, Sun JH, Ma WQ, Wang JJ, Sun GJ. Effects of Omega-3 Fatty Acids Supplementation on Serum Lipid Profile and Blood Pressure in Patients with Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Foods. 2023;12(4):725. doi:10.3390/foods12040725
6. Jain AP, Aggarwal KK, Zhang PY. Omega-3 fatty acids and cardiovascular disease. Eur Rev Med Pharmacol Sci. 2015;19(3):441-445.
7. Vanhees L, Defoor JG, Schepers D, et al. Effect of bisoprolol and atenolol on endurance exercise capacity in healthy men. J Hypertens. 2000;18(1):35-43. doi:10.1097/00004872-200018010-00006
8. Kawashima H, Akimoto K, Jareonkitmongkol S, Shirasaka N, Shimizu S. Nicardipine and nifedipine inhibit fatty acid desaturases in rat liver microsomes. Biosci Biotechnol Biochem. 1996;60(10):1672-1676. doi:10.1271/bbb.60.1672

9. Joos C, Kewitz H, Reinhold-Kourniati D. Effects of diuretics on plasma lipoproteins in healthy men. Eur J Clin Pharmacol. 1980;17(4):251-257. doi:10.1007/BF00625798
10. Jula A, Marniemi J, Rönnemaa T, Virtanen A, Huupponen R. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men: a randomized controlled trial. Arterioscler Thromb Vasc Biol. 2005;25(9):1952-1959. doi:10.1161/01.ATV.0000177812.84927.fa
11. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339
12. BLIGH EG, DYER WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911-917. doi:10.1139/o59-099
13. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease?. Prev Med. 2004;39(1):212-220. doi:10.1016/j.ypmed.2004.02.030
14. Abe Y, Okada T, Iguchi H, et al. Association of changes in body fatness and fatty acid composition of plasma phospholipids during early puberty in Japanese children. J Atheroscler Thromb. 2012;19(12):1102-1109. doi:10.5551/jat.12476
15. Gerber RT, Holemans K, O'Brien-Coker I, et al. Cholesterol-independent endothelial dysfunction in virgin and pregnant rats fed a diet high in saturated fat. J Physiol. 1999;517(Pt 2):607-616. doi:10.1111/j.1469-7793.1999.0607t.x
16. Zheng ZJ, Folsom AR, Ma J, Arnett DK, McGovern PG, Eckfeldt JH. Plasma fatty acid composition and 6-year incidence of hypertension in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol. 1999;150(5):492-500. doi:10.1093/oxfordjournals.aje.a010038
17. Chen P, Liu H, Xiang H, et al. Palmitic acid-induced autophagy increases reactive oxygen species via the Ca2+/PKCα/NOX4 pathway and impairs endothelial function in human umbilical vein endothelial cells. Exp Ther Med. 2019;17(4):2425-2432. doi:10.3892/etm.2019.7269
18. Mu L, Mukamal KJ, Naqvi AZ. Erythrocyte saturated fatty acids and systemic inflammation in adults. Nutrition. 2014;30(11-12):1404-1408. doi:10.1016/j.nut.2014.04.020
19. Davda RK, Stepniakowski KT, Lu G, Ullian ME, Goodfriend TL, Egan BM. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism. Hypertension. 1995;26(5):764-770. doi:10.1161/01.hyp.26.5.764
20. Grynberg A. Hypertension prevention: from nutrients to (fortified) foods to dietary patterns. Focus on fatty acids. J Hum Hypertens. 2005;19(Suppl 3):25-33. doi:10.1038/sj.jhh.1001957
21. Morris MC, Sacks F, Rosner B. Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation. 1993;88(2):523-533. doi:10.1161/01.cir.88.2.523
22. Ebbesson SO, Lopez Alvarenga JC, Okin PM, et al. Heart rate is associated with markers of fatty acid desaturation: the GOCADAN study. Int J Circumpolar Health. 2012;71:17343. doi:10.3402/ijch.v71i0.17343
23. Warensjö E, Sundström J, Vessby B, Cederholm T, Risérus U. Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr. 2008;88(1):203-209. doi:10.1093/ajcn/88.1.203
24. Daneshmand R, Kurl S, Tuomainen TP, Virtanen JK. Associations of estimated Δ-5-desaturase and Δ-6-desaturase activities with stroke risk factors and risk of stroke: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr. 2017;117(4):582-590. doi:10.1017/S000711451700054X
25. Yang B, Ding F, Wang FL, et al. Association of serum fatty acid and estimated desaturase activity with hypertension in middle-aged and elderly Chinese population. Sci Rep. 2016;6:23446. doi:10.1038/srep23446
26. Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294(19):2455-2464. doi:10.1001/jama.294.19.2455
27. Jakobsen MU, O'Reilly EJ, Heitmann BL, et al. Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr. 2009;89(5):1425-1432. doi:10.3945/ajcn.2008.27124
28. Hiltunen TP, Rimpelä JM, Mohney RP, Stirdivant SM, Kontula KK. Effects of four different antihypertensive drugs on plasma metabolomic profiles in patients with essential hypertension. PLoS One. 2017;12(11):e0187729. doi:10.1371/journal.pone.0187729
29. Watanabe S, Tagawa T, Yamakawa K, Shimabukuro M, Ueda S. Inhibition of the renin-angiotensin system prevents free fatty acid-induced acute endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2005;25(11):2376-2380. doi:10.1161/01.ATV.0000187465.55507.85
30. Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995;44(6):665-671. doi:10.2337/diab.44.6.665
31. Hsieh CC, Chiu HH, Wang CH, Kuo CH. Aspirin Modifies Inflammatory Mediators and Metabolomic Profiles and Contributes to the Suppression of Obesity-Associated Breast Cancer Cell Growth. Int J Mol Sci. 2020;21(13):4652. doi:10.3390/ijms21134652
32. Onay Besikci A, Suzmecelik E, Ozcelikay AT. Carvedilol suppresses fatty acid oxidation and stimulates glycolysis in C2C12 cells. Can J Physiol Pharmacol. 2012;90(8):1087-1093. doi:10.1139/y2012-015
33. Newman RJ. Comparison of the antilipolytic effect of metoprolol, acebutolol, and propranolol in man. Br Med J. 1977;2(6087):601-603. doi:10.1136/bmj.2.6087.601
34. Zawadzka K, Bernat P, Felczak A, Różalska S, Lisowska K. Antibacterial activity of high concentrations of carvedilol against Gram-positive and Gram-negative bacteria. Int J Antimicrob Agents. 2018;51(3):458-467. doi:10.1016/j.ijantimicag.2017.12.014
35. Shearer GC, Carrero JJ, Heimbürger O, Barany P, Stenvinkel P. Plasma fatty acids in chronic kidney disease: nervonic acid predicts mortality. J Ren Nutr. 2012;22(2):277-283. doi:10.1053/j.jrn.2011.05.005